Income statement, balance sheet and cash flow statement for the last 6 fiscal years, taken from the XBRL data Altamira Therapeutics Ltd. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2018
FY2020
FY2020
FY2022
FY2024
FY2024
Research and development
15.3
3.38
3.73
Selling, general and administrative
3.56
3.49
3.2
Selling and marketing
0.21
General and administrative
2.64
2.53
2.15
Operating income
-18.9
-6.58
-6.85
Interest income
0.59
0.39
0
Pre-tax income
-19.5
-8.09
-8.46
Income tax
-0.01
Income from continuing operations
-19.5
-8.09
-8.46
Net income
-11.5
-6.63
-8.2
-27.8
-4.31
-8.46
EPS, basic
-14.46
-2.28
-1.36
-610.03
-8.77
-2.99
EPS, diluted
-14.46
-2.28
-1.36
-610.03
-8.77
-2.99
Balance sheet
FY2018
FY2020
FY2020
FY2022
FY2024
FY2024
Cash and equivalents
0.02
0.73
1
Total current assets
1.45
1.54
Property, plant and equipment
0
0.1
Lease right-of-use assets
0.1
0.35
Intangible assets
4.63
4.63
Total assets
9.14
8.65
Accounts payable
0.52
0.55
Total current liabilities
1.06
1.16
Lease liabilities
0.24
Total liabilities
1.47
2.09
Total debt
5.29
Paid-in capital
23.9
-1.52
Retained earnings
-21.3
-3.03
Shareholders' equity
7.68
6.57
Total equity
-8.99
7.68
6.57
Total liabilities and equity
9.14
8.65
Cash flow statement
FY2018
FY2020
FY2020
FY2022
FY2024
FY2024
Net income
-11.5
-6.63
-8.2
-27.8
-4.31
-8.46
Cash from operations
-9.09
-12.8
-6.11
Capital expenditures
-0.1
Cash from investing
-2.24
1.61
-0.12
Stock issued
5
3.99
Cash from financing
10.3
11.8
6.51
Exchange rate effect
-0.02
0.1
-0.01
Net change in cash
-1.04
0.62
0.28
Free cash flow
-6.22
Key metrics
Worked out from the statements above. Latest values use fiscal 2024. Valuation uses the share price of $0.06 on September 28, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-118.8%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-95.1%
Net income / average total assets.
Return on invested capital (ROIC)
-60.8%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
-14.5%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-5.4%
Total assets vs the same period a year earlier. Only from a positive base.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.32x
Current assets / current liabilities.
Quick ratio
0.86x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.86x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$2.99
Net income per basic share, as reported (split-adjusted).
Valuation
Metric
Value
How it is calculated
Market cap
$296.0K
Share price x shares outstanding.
Enterprise value
-$702.6K
Market cap + total debt - cash - short-term investments.
P/B
0.05x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.15x
Market cap / tangible book value, when positive.
FCF yield
-2,100.0%
Free cash flow / market cap.
Earnings yield
-2,857.0%
Net income / market cap (the inverse of P/E).
Was Altamira Therapeutics Ltd. profitable in fiscal 2024?
No. It reported a net loss of $8.5M.
How much free cash flow did Altamira Therapeutics Ltd. generate in fiscal 2024?
Cash from operations of $6.1M minus capital expenditures of $103.1K left free cash flow of -$6.2M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.